Compass Therapeutics
Market cap $109M 180.1M shares (10-Q, Nov 5, 2026) × $0.607 close Nov 17, 2026
Most recent annual filing: 2026-03-05
- Tovecimig Ph2 start2H 2026Tovecimig Ph2 start, 2H 2026, routine
- Tovecimig BLA filing4Q 2026Tovecimig BLA filing, 4Q 2026, material
- CTX-8371 Ph1 readout4Q 2026CTX-8371 Ph1 readout, 4Q 2026, notable
- CTX-10726 Ph1 readout4Q 2026CTX-10726 Ph1 readout, 4Q 2026, notable
- Tovecimig FDA approval2H 2027Tovecimig FDA approval, 2H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (15 active programs)
CTX-471
- Melanoma
- Small Cell Lung Cancer
- Mesothelioma
- Undisclosed indication
CTX-8371
CTX-10726
- Undisclosed indication
- Renal Cell Carcinoma
- Gastroesophageal Cancer
- Hepatocellular Carcinoma
- Endometrial Cancer
Technology platforms
StitchMabs
Bispecific antibody discovery platform using combinatorial screening of antigen-binding domain pairs across innate and adaptive immune targets; used to identify novel bispecific antibodies for oncology applications
Capital (as filed)
- Cash
- $41.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $122M Sep 30, 2026
- Operating cash flow
- −$16.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $163M cash, runway into 2028 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (4)
- 2026-11-10 UPDATE: Compass Therapeutics (CMPX) - Spending Through It 🔒 Paid
- 2026-10-27 UPDATE: Compass Therapeutics (CMPX) - The ESMO Receipts Came In 🔒 Paid
- 2026-09-23 UPDATE: Compass Therapeutics (CMPX) - The FDA Asked for the One Thing They Can’t Afford 🔒 Paid
- 2026-08-25 Compass Therapeutics (CMPX) — Scientific Deep Dive for Tovecimig and the Bispecific Antibody Pipeline
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (4 calls)
Every verdict Biotech Distilled has published on Compass Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-08-25 Watch Compass Therapeutics (CMPX) — Scientific Deep Dive for Tovecimig and the Bispecific Antibody Pipeline Strong randomized PFS signal and unmet need at a discounted valuation, but the only pre-specified crossover-adjusted survival analysis came back at HR 1.13 and duration of response is still unpublished; wait for FDA meeting outcome and ESMO data before committing.
- 2026-09-23 Avoid UPDATE: Compass Therapeutics (CMPX) - The FDA Asked for the One Thing They Can't Afford FDA recommended a new survival trial before any BLA — the pre-named PASS condition — and the $179.9M balance sheet cannot fund a randomized OS study plus a commercial build plus three early-stage programs.
- 2026-10-27 Avoid UPDATE: Compass Therapeutics (CMPX) - The ESMO Receipts Came In Full COMPANION-002 dataset shows a middling 4.9-month DOR, 27.8% discontinuation rate, and a post-hoc non-significant survival adjustment (HR 0.85, p=0.53) that does not plausibly overturn the FDA's call for a survival trial this balance sheet cannot fund.
- 2026-11-10 Avoid UPDATE: Compass Therapeutics (CMPX) - Spending Through It Q3 10-Q shows tovecimig manufacturing spend nearly quintupling and pre-commercial G&A continuing after the FDA recommended a survival trial, eroding the cash floor faster than the reported burn rate implies.
- Avoid call · opened Sep 23, 2026 at $1.17 · -48.1% vs XBI -6.4% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (20)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 22, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseCompass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE→ BD updateThe Q3 10-Q answers the question the October ESMO update left open: Compass is burning cash at an accelerating rate — $27M net loss in Q3 alone, $163M remaining, pre-commercialization spend continuing — while keeping the ATM untouched and pressing forward toward a BLA the FDA told them to hold.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 6, 2026ReleaseCompass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
- Nov 2, 2026ReleaseCompass Therapeutics to Participate in Upcoming November Investor Events
- Oct 24, 2026ReleaseCompass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026→ BD updateBD extracted 1 program update from this document → CMPX pipeline
- Sep 22, 2026ReleaseCompass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback→ BD updateSummary on the 8-K
- Sep 22, 20268-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE→ BD updateThe FDA told Compass it needs a new survival trial before filing a BLA for tovecimig — the exact bear-case outcome the prior writeup named as a PASS trigger. The stock is down ~48% and the thesis, as written, is broken.BD extracted 1 program update from this document → CMPX pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
- Aug 6, 202610-QQuarterly report
- Jul 1, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Jun 23, 20268-KCurrent report: charter / bylaws / fiscal year
- Jun 11, 20268-KCurrent report: shareholder vote
- May 5, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
- May 5, 202610-QQuarterly report
- Apr 29, 2026DEFA14AProxy soliciting material
- Apr 29, 2026DEF 14AProxy statement
- Apr 27, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 PRESS RELEASE
- Mar 5, 20268-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
- Mar 5, 202610-KAnnual report
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 29, 2026ARSAnnual report to shareholders
- Mar 12, 2026S-8Employee plan registration